Cargando…
Clinical consequences of off-label reduced dosing of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a systematic review and meta-analysis
OBJECTIVE: Postmarketing observational studies report that a substantial percentage of patients with atrial fibrillation (AF) receive a reduced non-vitamin K antagonist oral anticoagulant (NOAC) dose without a clear indication. Recently, increasing evidence has become available to explore the clinic...
Autores principales: | Joosten, Linda P T, van Maanen, Rosanne, van den Dries, Carline J, Rutten, Frans H, Hoes, Arno W, Granger, Christopher B, Hemels, Martin E W, Geersing, Geert-Jan, van Doorn, Sander |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10410991/ https://www.ncbi.nlm.nih.gov/pubmed/37169490 http://dx.doi.org/10.1136/openhrt-2022-002197 |
Ejemplares similares
-
Safety of off‐label dose reduction of non‐vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
por: van den Dries, Carline J., et al.
Publicado: (2022) -
Safety of switching from vitamin K antagonist to non-vitamin K antagonist oral anticoagulant in frail elderly with atrial fibrillation: rationale and design of the FRAIL-AF randomised controlled trial
por: Joosten, Linda P T, et al.
Publicado: (2019) -
The Number of Concomitant Drugs and the Safety of Direct Oral Anticoagulants in Routine Care Patients with Atrial Fibrillation
por: van den Dries, Carline J., et al.
Publicado: (2020) -
Estimated causal effects of common respiratory infections on cardiovascular risk: a meta-analysis
por: la Roi-Teeuw, Hannah M, et al.
Publicado: (2023) -
Integrated management of atrial fibrillation including tailoring of anticoagulation in primary care: study design of the ALL-IN cluster randomised trial
por: van den Dries, Carline J, et al.
Publicado: (2017)